Lalitha K Shankar
Overview
Explore the profile of Lalitha K Shankar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ellingson B, Sanvito F, Pope W, Cloughesy T, Huang R, Villanueva-Meyer J, et al.
AJNR Am J Neuroradiol
. 2024 Dec;
46(1):221-222.
PMID: 39730160
No abstract available.
2.
Ellingson B, Sanvito F, Cloughesy T, Huang R, Villanueva-Meyer J, Pope W, et al.
AJNR Am J Neuroradiol
. 2024 Jun;
45(12):1846-1856.
PMID: 38926092
Radiographic assessment plays a crucial role in the management of patients with central nervous system (CNS) tumors, aiding in treatment planning and evaluation of therapeutic efficacy by quantifying response. Recently,...
3.
Harris L, Shankar L, Hildebrandt C, Rubinstein W, Langlais K, Rodriguez H, et al.
J Natl Cancer Inst
. 2024 Jun;
116(10):1562-1570.
PMID: 38867688
The National Institutes of Health-US Food and Drug Administration Joint Leadership Council Next-Generation Sequencing and Radiomics Working Group was formed by the National Institutes of Health-Food and Drug Administration Joint...
4.
Eary J, Shankar L, Freymann J, Kirby J
Radiol Imaging Cancer
. 2024 May;
6(3):e240098.
PMID: 38819266
No abstract available.
5.
Wen P, van den Bent M, Youssef G, Cloughesy T, Ellingson B, Weller M, et al.
J Clin Oncol
. 2023 Sep;
41(33):5187-5199.
PMID: 37774317
Purpose: The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time, some...
6.
Shankar L, Schoder H, Sharon E, Wolchok J, Knopp M, Wahl R, et al.
Lancet Oncol
. 2023 Mar;
24(3):e133-e143.
PMID: 36858729
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy...
7.
Huang E, OConnor J, McShane L, Giger M, Lambin P, Kinahan P, et al.
Nat Rev Clin Oncol
. 2022 Nov;
20(2):69-82.
PMID: 36443594
Computer-extracted tumour characteristics have been incorporated into medical imaging computer-aided diagnosis (CAD) algorithms for decades. With the advent of radiomics, an extension of CAD involving high-throughput computer-extracted quantitative characterization of...
8.
Shankar L, Huang E, Litiere S, Hoekstra O, Schwartz L, Collette S, et al.
Clin Cancer Res
. 2022 Oct;
29(1):143-153.
PMID: 36302172
Purpose: Currently, guidelines for PET with 18F-fluorodeoxyglucose (FDG-PET) interpretation for assessment of therapy response in oncology primarily involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of the metabolic activity...
9.
Schoder H, Hope T, Knopp M, Kelly W, Michalski J, Lerner S, et al.
J Clin Oncol
. 2022 Jan;
40(13):1500-1505.
PMID: 35015566
Purpose: As prostate-specific membrane antigen (PSMA) positron emission tomography (PET) becomes increasingly available in the United States, the greater sensitivity of the technology in comparison to conventional imaging poses challenges...
10.
Gambhir S, Shankar L, Rosenthal E, Warram J, Ghesani M, Hope T, et al.
J Nucl Med
. 2019 Mar;
60(6):736-744.
PMID: 30850482
No abstract available.